Durysta Microimplant System offering more Glaucoma Options
Dr. Rishi Kumar MD has recently started offering a new micro implant for helping patients better control their intraocular pressure, the number one risk factor in Glaucoma progression. The Durysta implant is a tiny biodegradable poylmer matrix that contains 10 mcg of Bimatoprost which is slowly eluted from the implant to control pressure for a period of 12 weeks. The tube is less than 1 mm in length and delivered through a small 27 gauge needle after carefully anesthetizing the eye. As you can see in Figure 2, this device is FDA approved for the ability to lower IOP by up to 33% with a favorable side effect profile. The system is an effective alternative for those patients who have trouble keeping up with their drop regiment.
Cutting Edge Intraocular Lens Technology
The latest technological advance in the mission to restore natural vision after cataract surgery is available to you at Kumar Eye in the
Synergy Tecnis Lens
from Johnson &Johnson. Dr. Rishi Kumar MD was the first Ophthalmologist in Kentucky to utilize this lens with cataract surgery after it became FDA approved in May 2021.In the right candidate, it can provide continuous, high contrast vision from far to near eliminating the need for corrective glasses.
CLINICAL REVIEW OF THE QUARTER: Diabetic Eye Disease
Nearly 10% of the U.S. Population have been diagnosed with Diabetes. Studies suggest that only 40% of those patients are getting recommended eye exams (#1). The Diabetic Eye Exam is a critical surveillance tool for preventing vision loss which can develop from damage to the blood vessels of the retina visualized as swelling, leakage, or growth in a proliferative fashion on fundoscopic examination.
The figures below demonstrate various stages of diabetic eye disease that have been detected and treated by our Physicians at Kumar Eye Institute.
The clinical photos above from left to right demonstrate common manifestations of Diabetic Eye Disease seen and treated by our physicians. Proliferative Diabetic Retinopathy is seen in Figure 6. Figure 7 is a Ocular Coherence Tomography (OCT) scan of the retina which shows Diabetic Macular Edema (DME) before and aftertreatment with a intravitreal injection performed in the office. Vision for this particular KEI patient with DME improved from 20/100 to 20/25 after two injections of a Anti-VEGF (Vascular Endothelial Growth Factor)Compound (resolution demonstrated in Figure 8). Figure 9 is a patient with Neovascularization of the Iris seen in Severe Proliferative Diabetic Retinopathy which can lead to dangerous intraocular pressures and permanent vision loss. Encourage your patients to follow the American Academy of Ophthalmology guidelines by getting annual Diabetic Exams with KEI.
Their vision will thank you for it!
KEI PARTNERSHIP WITH THE UNIVERSITY OF LOUISVILLE
Dr. Ashima Gupta (Board Certified
Ophthalmologist) has been named a Clinical Assistant Professor in Ophthalmology with the University of Louisville and will now offer the opportunity for training residents to perform shadow rotations as part of their Pediatric Ophthalmology training. KEI is proud to give back to the field of Ophthalmology in a way that ensures that the future generation of Ophthalmologists will be available to provide quality care for our community for years to come.